Lively Biotech has obtained optimistic suggestions from regulators on a protocol modification to its ongoing proof-of-concept scientific trial evaluating tasquinimod in sufferers with myelofibrosis, a...
The U.S. Meals and Drug Administration (FDA) has accepted PD-L1 IHC 22C3 pharmDx, Code SK006, as a companion diagnostic to assist establish sufferers with epithelial...
Though endocrine remedy together with a CDK4/6 inhibitor stays the first frontline remedy choice for sufferers with estrogen receptor (ER)–optimistic/HER2-negative metastatic breast most...
